Liam King

PhD Candidate and Adjunct Lecturer

Griffith University

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Liam King is a PhD Candidate and Adjunct Lecturer at Griffith University in Australia. His research focuses on oncology and pharmacology, with recent articles exploring topics such as the impact of cancer care programs on employee knowledge and retention, radioresistance in prostate cancer, and the use of COX-2 inhibitors in cancer treatment. He is actively involved in studies aimed at improving clinical outcomes for cancer patients through innovative therapeutic approaches.

Articles (7)

Year:

2025

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Catherine McDermott

Bond University

AUSTRALIA

View details

Stephen Ralph

Griffith University

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Liam King

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Development and implementation of a pharmacy introductory cancer care program: Impacts on employee knowledge, engagement and retention

Drivers of Radioresistance in Prostate Cancer

Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside

Trimethoprim‐sulfamethoxazole as Pneumocystis jiroveci pneumonia prevention in patients undergoing methotrexate therapy for hematological malignancies: A review of the literature

Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation

The COX-2 inhibitor NS398 selectively sensitizes hypoxic HeLa cells to ionising radiation by mechanisms both dependent and independent of COX-2

Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study

Collaborators (2)

Catherine McDermott

Stephen Ralph

Make your next move.